Building the decision layer pharma R&D is missing.
Decivio was built around real pain points raised by pharma leaders: fragmented signals, underweighted competition, implicit go decisions and weak post-board follow-up. Our conviction is simple, the next bottleneck in pharma R&D is not information. It is decision velocity under uncertainty.
What we believe about good decisions.
Decivio does not decide
The platform structures the arbitration, makes conditions explicit and keeps the decision traceable. Scientific and strategic judgment remains with your teams.
Work with the rituals
Boards, committees, board packs and PowerPoint are not going away. Decivio generates the decision pages, it does not fight the ritual.
No magic claims
Decivio does not promise to eliminate scientific failure. It targets the avoidable part of value leakage, delayed, implicit, unconditioned decisions.
One decision. Eight perspectives.
Critical R&D decisions involve many functions with different concerns. Decivio gives each one a clear place in the arbitration.
| Persona | Primary concern | What Decivio changes |
|---|---|---|
| CEO / General Manager | Competitiveness, speed, capital, governance discipline | Better and faster critical R&D arbitrations |
| Head of R&D / CMO | Progression decisions, clarity of evidence, coordination | Structured go / hold / stop decisions with explicit conditions |
| Portfolio & Strategy | Capital allocation, prioritization, competition | Comparable decisions and explicit capital at risk |
| Clinical Development | Endpoints, design, clinical signals, phase transitions | Clinical evidence turned into clear decision options |
| Safety | Benefit-risk, alert signals, follow-up conditions | Safety reserves made actionable via triggers and re-review |
| Regulatory | Endpoint acceptability, rationale, traceability | Formalized rationale and regulatory conditions |
| Clinical Operations / CRO | Sites, recruitment, timelines, feasibility | Operational signals linked to trial-design and re-scope decisions |
| Finance / CFO | Committed capital, cost of delay, allocation | Capital at risk and the cost of indecision quantified |
DECIVIO · PARIS
Close to the science. Closer to the decision.
We work side by side with R&D, portfolio and finance teams, in their language and their rituals. Every engagement starts from a real decision, not a software demo. That is how a governance layer earns its place in a boardroom.
Decivio was built in collaboration with experts from Novartis, Pierre Fabre and biotech companies across North America, shaped by the real decision pressures of global R&D organizations.
A competitiveness lever teams actually control.
European pharma faces intensifying global competition and pressure on clinical attractiveness. Decivio does not act on pricing or reimbursement, it acts on a lever R&D organizations fully control: the speed, quality and discipline of their own decisions.
Let's talk about your next tollgate.
A strategic conversation, not a product tour.